Description
Tirzepatide is a first-in-class “twincretin” — a single synthetic peptide molecule that simultaneously agonizes both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, combining two incretin hormone signaling pathways in a once-weekly injectable format.
Research Overview
The SURMOUNT clinical program has produced some of the most discussed weight loss data in recent metabolic research history. SURMOUNT-1 (New England Journal of Medicine, 2022) demonstrated mean weight reductions of 20.9% at the highest dose over 72 weeks — exceeding results observed with GLP-1 agonist monotherapy and establishing dual incretin co-activation as a distinct pharmacological strategy. The additional efficacy versus GLP-1-only agonists has been mechanistically attributed to GIP receptor activation in adipose tissue, where GIP signaling appears to enhance lipid metabolism and insulin sensitivity through pathways distinct from GLP-1. The SURPASS diabetes program (7 trials, Lancet/NEJM, 2021-2022) established robust HbA1c reductions across diverse patient populations including those on basal insulin. The SYNERGY-NASH Phase 2 trial demonstrated histological resolution of steatohepatitis with fibrosis improvement in a substantial proportion of participants. The SUMMIT trial (Lancet, 2024) reported significant improvements in exercise capacity and functional outcomes in heart failure with preserved ejection fraction. Research teams building on this dataset continue to examine the mechanistic basis for dual incretin receptor co-activation across metabolic, hepatic, cardiovascular, and renal endpoints.
Key References
- Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.
- Ludvik B et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec (SURPASS-3). The Lancet.
- Bhatt DL et al. (2024). Tirzepatide for Heart Failure with Preserved Ejection Fraction (SUMMIT). The Lancet.
Reviews
There are no reviews yet.